EA017443B1 - Производные тетрагидрохинолина для лечения посттравматических стрессовых расстройств - Google Patents

Производные тетрагидрохинолина для лечения посттравматических стрессовых расстройств Download PDF

Info

Publication number
EA017443B1
EA017443B1 EA201000557A EA201000557A EA017443B1 EA 017443 B1 EA017443 B1 EA 017443B1 EA 201000557 A EA201000557 A EA 201000557A EA 201000557 A EA201000557 A EA 201000557A EA 017443 B1 EA017443 B1 EA 017443B1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
pharmaceutically acceptable
compound
compounds
acceptable salt
Prior art date
Application number
EA201000557A
Other languages
English (en)
Russian (ru)
Other versions
EA201000557A1 (ru
Inventor
Франсуа Женк
Original Assignee
Актелион Фармасьютиклз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA017443(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Актелион Фармасьютиклз Лтд. filed Critical Актелион Фармасьютиклз Лтд.
Publication of EA201000557A1 publication Critical patent/EA201000557A1/ru
Publication of EA017443B1 publication Critical patent/EA017443B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
EA201000557A 2007-10-10 2008-10-09 Производные тетрагидрохинолина для лечения посттравматических стрессовых расстройств EA017443B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2007054130 2007-10-10
PCT/IB2008/054138 WO2009047723A2 (fr) 2007-10-10 2008-10-09 Dérivés de tétrahydroquinoléine pour traiter des troubles de stress post-traumatique

Publications (2)

Publication Number Publication Date
EA201000557A1 EA201000557A1 (ru) 2010-10-29
EA017443B1 true EA017443B1 (ru) 2012-12-28

Family

ID=40467356

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000557A EA017443B1 (ru) 2007-10-10 2008-10-09 Производные тетрагидрохинолина для лечения посттравматических стрессовых расстройств

Country Status (28)

Country Link
US (1) US9532985B2 (fr)
EP (1) EP2207550B1 (fr)
JP (1) JP5883222B2 (fr)
KR (1) KR101733247B1 (fr)
CN (1) CN101820878B (fr)
AR (1) AR068768A1 (fr)
AU (1) AU2008309194B2 (fr)
BR (1) BRPI0818617A2 (fr)
CA (1) CA2699504C (fr)
CY (1) CY1114799T1 (fr)
DK (1) DK2207550T3 (fr)
EA (1) EA017443B1 (fr)
ES (1) ES2444418T3 (fr)
HK (1) HK1145440A1 (fr)
HR (1) HRP20140214T1 (fr)
IL (1) IL204838A (fr)
MA (1) MA31800B1 (fr)
MX (1) MX2010003711A (fr)
MY (1) MY153044A (fr)
NZ (1) NZ585086A (fr)
PE (1) PE20091010A1 (fr)
PL (1) PL2207550T3 (fr)
PT (1) PT2207550E (fr)
SI (1) SI2207550T1 (fr)
TW (1) TWI428129B (fr)
UA (1) UA99150C2 (fr)
WO (1) WO2009047723A2 (fr)
ZA (1) ZA201003251B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010513466A (ja) 2006-12-22 2010-04-30 アクテリオン ファーマシューティカルズ リミテッド ５，６，７，８−テトラヒドロ−イミダゾ［１，５−ａ］ピラジン誘導体
CN102076694A (zh) 2008-06-25 2011-05-25 埃科特莱茵药品有限公司 5，6，7，8-四氢-咪唑并[1，5-a]吡嗪化合物
EP2402322A1 (fr) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. Dérivé de 1,2,3,4-tétrahydroisoquinoline et son utilisation comme antagoniste du récepteur de l'orexine
JP5744203B2 (ja) 2010-08-24 2015-07-08 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体
PT2626350E (pt) 2010-09-22 2015-08-03 Eisai R&D Man Co Ltd Composto de ciclopropano
US9242970B2 (en) 2010-11-10 2016-01-26 Actelion Pharmaceuticals Ltd. Lactam derivatives useful as orexin receptor antagonists
WO2012085852A1 (fr) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-8-ylamides
ES2541531T3 (es) 2011-02-18 2015-07-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirazol e imidazol útiles como antagonistas de orexina
WO2012114252A1 (fr) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Nouveaux amides d'indole et de pyrrolopyridine
WO2013050938A1 (fr) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd Dérivés de 3,7-diazabicyclo[3.3.1]nonane et de 9-oxa-3,7- diazabicyclo[3.3.1]nonane
AR088692A1 (es) 2011-11-08 2014-06-25 Actelion Pharmaceuticals Ltd Derivados de 2-(1,2,3-triazol-2-il)benzamina y 3-(1,2,3-triazol-2-il)picolinamida
DK2855453T3 (en) 2012-06-04 2017-02-06 Actelion Pharmaceuticals Ltd Benzimidazol-proline derivatives
BR112015007516A2 (pt) 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
EP2970241A1 (fr) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Dérivés d'amide d'azétidine en tant qu'antagonistes des récepteurs d'oréxine
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
MX364208B (es) 2013-12-03 2019-04-16 Idorsia Pharmaceuticals Ltd Forma cristalina de (s)-(2-(6-cloro)-7-metil-1h-benzo[d]imidazol-2 -il)-2-metilpirrolidin-1-il) (5-metoxi-2-(2h-1,2,3-triazol-2-il)fe nil) metanona y su uso como antagonistas de receptor de orexina.
KR102330133B1 (ko) 2013-12-04 2021-11-23 이도르시아 파마슈티컬스 리미티드 벤즈이미다졸-프롤린 유도체의 용도
CN107810006B (zh) 2014-10-23 2021-03-30 卫材R&D管理有限公司 用于治疗失眠的组合物
CN115710250A (zh) * 2017-08-01 2023-02-24 博健制药有限责任公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途
WO2020007964A1 (fr) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd Dérivés de 2-(2-azabicyclo [3.1.0] hexan-1-yl)-1h-benzimidazole
WO2020007977A1 (fr) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd Dérivés de 7-trifluorométhyl-[1,4]diazépane
WO2020099511A1 (fr) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Dérivés de benzimidazole-2-méthyl-morpholine
WO2023218023A1 (fr) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Dérives d'hydrazine-n-carboxamide cycliques substitués par thiazoloaryl-méthyle

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068609A1 (fr) * 2000-03-14 2001-09-20 Actelion Pharmaceuticals Ltd. Derives de 1,2,3,4-tetrahydroisoquinoline
WO2004085403A1 (fr) * 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Derives de tetrahydro-isoquinolyl-acetamide destines a servir d'antagonistes des recepteurs d'orexine
WO2005118548A1 (fr) * 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Derives de 1,2,3,4-tétrahydroisoquinoléine substitués
US20070160538A1 (en) * 2005-04-25 2007-07-12 Eisai Co., Ltd. Antianxiety drugs and a method of screening the same
WO2007105177A1 (fr) * 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Dérivés de tétrahydroisoquinoléine pour renforcer la fonction de la mémoire

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2402322A1 (fr) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. Dérivé de 1,2,3,4-tétrahydroisoquinoline et son utilisation comme antagoniste du récepteur de l'orexine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068609A1 (fr) * 2000-03-14 2001-09-20 Actelion Pharmaceuticals Ltd. Derives de 1,2,3,4-tetrahydroisoquinoline
WO2004085403A1 (fr) * 2003-03-26 2004-10-07 Actelion Pharmaceuticals Ltd Derives de tetrahydro-isoquinolyl-acetamide destines a servir d'antagonistes des recepteurs d'orexine
WO2005118548A1 (fr) * 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Derives de 1,2,3,4-tétrahydroisoquinoléine substitués
US20070160538A1 (en) * 2005-04-25 2007-07-12 Eisai Co., Ltd. Antianxiety drugs and a method of screening the same
WO2007105177A1 (fr) * 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Dérivés de tétrahydroisoquinoléine pour renforcer la fonction de la mémoire

Also Published As

Publication number Publication date
PT2207550E (pt) 2014-02-07
SI2207550T1 (sl) 2014-03-31
AU2008309194B2 (en) 2013-10-03
ZA201003251B (en) 2011-07-27
HRP20140214T1 (hr) 2014-04-11
MY153044A (en) 2014-12-31
MA31800B1 (fr) 2010-10-01
UA99150C2 (ru) 2012-07-25
JP2011500550A (ja) 2011-01-06
BRPI0818617A2 (pt) 2015-04-07
MX2010003711A (es) 2010-04-30
CN101820878B (zh) 2012-02-01
IL204838A0 (en) 2010-11-30
AR068768A1 (es) 2009-12-02
NZ585086A (en) 2012-03-30
WO2009047723A2 (fr) 2009-04-16
CN101820878A (zh) 2010-09-01
IL204838A (en) 2014-09-30
TW200932231A (en) 2009-08-01
CA2699504A1 (fr) 2009-04-16
HK1145440A1 (en) 2011-04-21
AU2008309194A1 (en) 2009-04-16
KR20100065203A (ko) 2010-06-15
US20100234420A1 (en) 2010-09-16
EA201000557A1 (ru) 2010-10-29
PE20091010A1 (es) 2009-08-08
US9532985B2 (en) 2017-01-03
WO2009047723A3 (fr) 2009-05-28
ES2444418T3 (es) 2014-02-25
JP5883222B2 (ja) 2016-03-09
KR101733247B1 (ko) 2017-05-08
CY1114799T1 (el) 2016-12-14
CA2699504C (fr) 2015-11-24
EP2207550A2 (fr) 2010-07-21
TWI428129B (zh) 2014-03-01
DK2207550T3 (da) 2014-01-27
EP2207550B1 (fr) 2013-12-11
PL2207550T3 (pl) 2014-05-30

Similar Documents

Publication Publication Date Title
EA017443B1 (ru) Производные тетрагидрохинолина для лечения посттравматических стрессовых расстройств
US20100249164A1 (en) Modulation of sleep with nr2b receptor antagonists
JP2020513005A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
EP1463499A1 (fr) Traitement des ruptures du rythme circadien
OA12554A (en) Use of GABA a inverse agonists in combination withnicotine receptor partial agonists, estrogen, sel ective estrogen modulators, or bitamin E for the treatment of cognitive disorders.
Lejoyeux et al. Serotonin syndrome: incidence, symptoms and treatment
US20060003985A1 (en) Enhancement of sleep with t-type calcium channel antagonists
JP2016074728A (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
Ikeda‐Sagara et al. Induction of prolonged, continuous slow‐wave sleep by blocking cerebral H1 histamine receptors in rats
KR20180101322A (ko) 뇌졸중으로부터의 회복을 위한 방법 및 조성물
TW200300672A (en) Treatment of cognitive failure
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
JP2019516698A (ja) 純粋な５−ｈｔ６受容体アンタゴニスト、アセチルコリンエステラーゼ阻害剤及びｎｍｄａ受容体アンタゴニストの３種類の組合せ
JPH10236979A (ja) 痴呆に使用するための複合製剤
EA023728B1 (ru) Терапевтическое средство от тревожных расстройств
US20110092486A1 (en) Ih channel inhibitors for the promotion of wakefulness
Chambers Role of the Cholinergic Pedunculopontine Nucleus in Parkinsonian Motor Deficits and Dyskinesia in Hemi-Parkinsonian Rats
CN114159568A (zh) Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
US20190365753A1 (en) Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages
Hemanthkumar Study of anticonvulsant activity of acetazolamide on albino rats and its influence on anticonvulsant activity of sodium valproate
Juncos Perioperative management of patients with Parkinson’s disease
Thiele Striatal mechanisms mediating parkinsonism and L-DOPA-induced dyskinesia: Contribution of the direct-and indirect-output pathways
TW200524920A (en) Treatment of circadian rhythm disorders with NPY Y5 receptor antagonist

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment